EyePoint Pharmaceuticals (EYPT) News Today $6.24 -0.10 (-1.58%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$6.31 +0.07 (+1.11%) As of 03/25/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and EyePoint Pharmaceuticals (EYPT)March 17, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)March 17, 2025 | globenewswire.comErste Asset Management GmbH Invests $360,000 in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Erste Asset Management GmbH bought a new position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at appMarch 16, 2025 | marketbeat.comStockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to "Sell"StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday.March 14, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)March 10, 2025 | markets.businessinsider.comResearch Analysts Set Expectations for EYPT FY2025 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for EyePoint Pharmaceuticals in a research report issued on Thursday, March 6th. Cantor Fitzgerald analyst J. Kim now expects that the company will post earnings per sharMarch 10, 2025 | marketbeat.comQ1 EPS Estimate for EyePoint Pharmaceuticals Cut by AnalystEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share estimates for shares of EyePoint Pharmaceuticals in a report released on Thursday, March 6th. HC Wainwright analyst Y. Chen now anticipates that the companMarch 10, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 7.4% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 7.4% - Here's What HappenedMarch 8, 2025 | marketbeat.comJonesTrading Remains a Buy on EyePoint Pharmaceuticals (EYPT)March 7, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan CapitalChardan Capital reissued a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday.March 7, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday.March 7, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | msn.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Releases Earnings Results, Misses Estimates By $0.10 EPSEyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.March 6, 2025 | marketbeat.comDespite Recent Gains, EyePoint Pharmaceuticals Insiders Are Still Down US$32kMarch 6, 2025 | finance.yahoo.comEyePoint Pharmaceuticals, Inc. (EYPT) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | seekingalpha.comEyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate DevelopmentsMarch 5, 2025 | globenewswire.comEyePoint Pharmaceuticals Q4 2024 Earnings PreviewMarch 4, 2025 | msn.comEyePoint Announces Participation at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from BrokeragesEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned an average rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month priceMarch 3, 2025 | marketbeat.comLevin Capital Strategies L.P. Purchases 44,000 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Levin Capital Strategies L.P. increased its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 440.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 54,000 shares of the company's stock afteMarch 2, 2025 | marketbeat.comEyePoint Pharmaceuticals (EYPT) Projected to Post Quarterly Earnings on ThursdayEyePoint Pharmaceuticals (NASDAQ:EYPT) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=670489)February 27, 2025 | marketbeat.comEYPT stock touches 52-week low at $5.9 amid sharp annual declineFebruary 26, 2025 | investing.comEyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025February 26, 2025 | globenewswire.comEyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 13.6% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 13.6% - Still a Buy?February 19, 2025 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 17, 2025 | globenewswire.comabrdn plc Purchases Shares of 230,745 EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)abrdn plc acquired a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 230,745 shares of the company's stock, valued at approximately $1,719,00February 11, 2025 | marketbeat.comScotiabank Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT)February 7, 2025 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for EyePoint Pharmaceuticals (NASDAQ:EYPT)Chardan Capital restated a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday.February 6, 2025 | marketbeat.comEyePoint Announces Positive 6-Month Data From Duravyu Trial For Diabetic Macular EdemaFebruary 6, 2025 | markets.businessinsider.comEyePoint stock jumps 10% on Duravyu study resultsFebruary 6, 2025 | msn.comEyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial ResultsFebruary 6, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten brokerages that are presently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy recommendation. The average 1-year target price amongFebruary 6, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year Low - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 1-Year Low - Here's What HappenedFebruary 5, 2025 | marketbeat.comCollegium appoints Nancy Lurker to board of directorsFebruary 5, 2025 | markets.businessinsider.comDURAVYU shows promise in Phase 2 trial for eye diseaseFebruary 5, 2025 | msn.comEyePoint's decline following positive data makes no sense, says analystFebruary 5, 2025 | investing.comEyePoint Pharmaceuticals stock sinks following clinical trial resultsFebruary 5, 2025 | msn.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest UpdateEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 31st total of 9,410,000 shares. Based on an average daily volume of 956,300 shares, the days-to-cover ratio is currently 10.8 days.February 2, 2025 | marketbeat.comEyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea RivalJanuary 30, 2025 | seekingalpha.comEyePoint to Present at Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comStrong week for EyePoint Pharmaceuticals (NASDAQ:EYPT) shareholders doesn't alleviate pain of one-year lossJanuary 25, 2025 | finance.yahoo.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 6.1% Higher - Should You Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 6.1% - Should You Buy?January 22, 2025 | marketbeat.comResearch Analysts Issue Forecasts for EYPT FY2025 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for EyePoint Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings peJanuary 22, 2025 | marketbeat.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Sees Large Increase in Short InterestEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 15th total of 9,410,000 shares. Based on an average daily volume of 956,300 shares, the short-interest ratio is currently 10.8 days.January 20, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)JPMorgan Chase & Co. boosted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 1,171.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 371,758 shares of the company's stJanuary 20, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 3.4% - Should You Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 3.4% Higher - What's Next?January 16, 2025 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 16, 2025 | globenewswire.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned an average rating of "Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1 year price target among brokJanuary 12, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.8% - Here's WhyEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.8% - Should You Sell?January 10, 2025 | marketbeat.com Remove Ads Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼1.890.77▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼14▲EYPT Articles Average Week Remove Ads Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXG News TRNS News CTKB News SENS News LAB News ALNT News QTRX News QSI News AEHR News FEIM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
